Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to nine new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The company, focused on developing therapeutics for serious retinal diseases, issued options to purchase up to 57,700 shares of common stock on July 15, 2024. These grants, approved by the Compensation Committee, have an exercise price of $10.54 per share, matching the closing price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments over the following three years, subject to continued employment.
EyePoint Pharmaceuticals will highlight the clinical and regulatory progress of DURAVYU™ (vorolanib intravitreal insert) and pipeline innovations at their R&D Day on June 26, 2024. Key updates include the Phase 3 trial design for LUGANO and LUCIA pivotal trials in wet AMD scheduled for 2H 2024 following a positive FDA meeting, and positive twelve-month safety and efficacy data from the Phase 2 DAVIO 2 trial. DURAVYU shows promise as a six-month maintenance therapy with no serious adverse events reported. The VERONA Phase 2 trial in diabetic macular edema has completed enrollment. EyePoint aims to advance DURAVYU as a significant treatment for VEGF-mediated retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced it will host an R&D Day on June 26, 2024, from 8:00 a.m. to 9:30 a.m. ET.
The event will feature esteemed KOL speakers Dr. Carl D. Regillo and Dr. Yasha S. Modi, who will discuss the science behind DURAVYU™ (vorolanib intravitreal insert).
The agenda includes an overview of DURAVYU™, positive Phase 2 DAVIO 2 trial results in wet AMD, and Phase 3 trial plans.
A roundtable discussion will be moderated by EyePoint's President and CEO, Jay S. Duker, M.D.
Access to the live event and replay is available on the EyePoint website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the issuance of non-statutory stock options to five new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4).
The grants, approved by the Compensation Committee, were made outside the 2023 Long-Term Incentive Plan.
A total of 25,000 shares of common stock were granted, with an exercise price of $9.38 per share, the closing price on June 14, 2024, the date of the grant.
The options vest over four years, with 25% vesting on the first anniversary of the grant date, and the remainder vesting monthly over the next three years, contingent on continued employment.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its President and CEO, Jay S. Duker, M.D., will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 3:20 p.m. ET. The presentation will be webcast live and available for replay for 90 days via EyePoint’s investor webpage. EyePoint is dedicated to developing and commercializing therapies for serious retinal diseases, aiming to enhance patient lives.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the granting of non-statutory stock options to four new employees as inducement awards outside the company's 2023 Long-Term Incentive Plan, adhering to NASDAQ Listing Rule 5635(c)(4). The grants, approved by the Compensation Committee, involve options to purchase a total of 44,200 shares of common stock. These options were issued on May 15, 2024, at an exercise price of $12.94 per share, the closing price of the stock on that date. The options have a ten-year term and vest over four years, with 25% vesting after the first year and the rest in monthly installments over the next three years, contingent on continued employment.
EyePoint Pharmaceuticals reported financial results for the first quarter of 2024 and highlighted recent corporate developments. The company has $299 million in cash and investments as of March 31, 2024, ensuring cash runway through Phase 3 trials for DURAVYU for wet AMD in 2026. Despite the Phase 2 PAVIA trial not meeting the primary endpoint, DURAVYU showed a biologic effect in patients with NPDR. EyePoint plans to initiate the Phase 3 LUGANO trial for DURAVYU in wet AMD and present Phase 2 VERONA trial data in 2025.
EyePoint Pharmaceuticals announced topline results of the Phase 2 PAVIA trial evaluating DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR). Although the trial did not meet the primary endpoint, DURAVYU demonstrated a favorable safety profile and potential in reducing NPDR progression at nine months. The Company plans to review full 12-month data to determine the future path for DURAVYU. Dr. Duker expressed optimism for DURAVYU's potential as a maintenance therapy for wet AMD patients based on positive data from DAVIO 2.
Summary not available.
Summary not available.
FAQ
What is the current stock price of EyePoint (EYPT)?
What is the market cap of EyePoint (EYPT)?
